Skip to main content
Ir a la página de inicio de la Comisión Europea (se abrirá en una nueva ventana)
español es
CORDIS - Resultados de investigaciones de la UE
CORDIS

Intelligent Personalised Disease Monitoring Device: a-Doc

Descripción del proyecto

Una muestra sencilla de saliva para controlar la actividad de las enfermedades autoinmunitarias

Las enfermedades autoinmunitarias, como la esclerosis múltiple y la artritis reumatoide, pueden ser graves y provocar un intenso dolor y sufrimiento. Además, los pacientes pueden tener que afrontar brotes impredecibles, a pesar del uso de medicación estable. El proyecto a-Doc, financiado con fondos europeos, propone un método para medir la actividad de las enfermedades autoinmunitarias de forma rápida y no invasiva en casa. Esta innovación de tecnología profunda utiliza un nuevo algoritmo de biomarcadores basado en una hormona liberadora de gonadotrofina, un biomarcador común a varias enfermedades autoinmunitarias. Basándose en este planteamiento, la solución de a-Doc usará una muestra de saliva para indicar la actividad de la enfermedad autoinmunitaria en cuestión y obtener un valor instantáneo fiable.

Objetivo

600m people globally suffer from autoimmune diseases such as rheumatoid arthritis (RA), psoriasis, and multiple sclerosis. The symptoms can be severe, causing intense pain and suffering for patients. The cost of RA alone for Europe is €45.3 billion p.a.

A growing need: Unlike diabetes patients for example who can measure their own blood sugar levels, there is currently no method to measure disease activity quickly and accurately for autoimmune patients, non-invasively at home. Furthermore, most autoimmune diseases have unpredictable flares in disease activity despite stable medication, and the causes of such flares differ between patients and are largely unidentifiable.

Our deep-tech innovation is an Artificial Intelligence approach to the Monitoring of Autoimmune Diseases at Home with a Novel Biomarker Algorithm: Through 15 years of research in this field, the founder of Kaass Discovery, Dr Anita Kaass, has shown a key biomarker, Gonadotropin releasing hormone (GnRH), is common to several autoimmune diseases. It has been scientifically shown that GnRH levels increase with increasing disease activity.

Kaass Discovery is developing a highly novel, deep tech solution to allow autoimmune disease patients to self-manage their conditions and minimize or even eliminate the symptoms of autoimmune diseases. The solution, which we call ‘a-Doc’, uses a saliva sample to indicate disease activity and provide an accurate, instantaneous value. In line with this need, it is also low cost, accurate and simple to use ensuring it is suitable for home use. The data collected from the device will be sent to the Kaass Discovery Cloud for improving the predictive analytical models, and giving an individualised meaningful result to the user on their mobile device

The aims of the Women TechEU programme align perfectly with the needs of Kaass Discovery. The business coaching support provided will ensure we are prepared and able to successfully commercialise this exciting technology.

Ámbito científico (EuroSciVoc)

Palabras clave

Programa(s)

Tema(s)

Régimen de financiación

HORIZON-CSA - HORIZON Coordination and Support Actions

Ver todos los proyectos financiados en el marco de este régimen de financiación

Convocatoria de propuestas

(se abrirá en una nueva ventana) HORIZON-EIE-2021-SCALEUP-01

Ver todos los proyectos financiados en el marco de esta convocatoria

Coordinador

KAASS DISCOVERY AS
Aportación neta de la UEn
€ 75 000,00
Dirección
SKRAPEKLEWEGEN 4
3937 Porsgrunn
Noruega
Pyme
Sí
Región
Norge Agder og Sør-Østlandet Vestfold og Telemark
Tipo de actividad
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Enlaces
Coste total
Sin datos